Vivo Capital, LLC
CIK 0001674712 · PALO ALTO, CA · Quarter end: 2026-06-30 · Filed on: 2026-08-14 · Open the SEC source ↗
Portfolio Value (AUM)Total value of the fund's US stock portfolio reported to the SEC.
$1.10B
2026 Q2
Positions
47
Top-10 ConcentrationHow much of the portfolio sits in the 10 largest holdings. High = concentrated bets.
52.4%
Est. Net Flow (Q)
—
2026 Q2
Top Holdings
TRVI
Trevi Therapeutics Inc
8.7%
PRAX
Praxis Precision Medicines
8.3%
ERAS
Erasca Inc
6.9%
AVBP
Arrivent BioPharma Inc
5.3%
ABVX
Abivax SA - ADR
5.0%
TNGX
Tango Therapeutics Inc
3.9%
CRVS
Corvus Pharmaceuticals Inc
3.8%
DRUG
Bright Minds Biosciences Inc
3.6%
New / Increased
No prior quarter data
Reduced / Exited
No prior quarter data
Read the 2026-Q2 quarterly report · 13F Filing Calendar
13F data shows quarter-end positions, is delayed by up to 45 days and covers only long positions in US-listed securities; short positions, most derivatives and non-US assets are not reported.